[Databricks in GlobeNewswire] Tevogen Bio commissions Databricks to accelerate development of PredicTcell, a precision AI tool for target prediction

WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence (AI), with an aim to accelerate the development of PredicTcell, the Company’s proprietary AI-driven target prediction model for precision immunotherapy.

Read more here.